Key Facts

• SBP Group, under the leadership of CEO Eric Tse, is planning to transition its business model from a generics-focused approach to a more innovative drug development strategy.
• The company's shift in focus was discussed during 'The World Economic Forum's Annual Meeting of the New Champions' in Dalian, where Eric Tse spoke with Bloomberg's Stephen Engle.
• Eric Tse's outlook for China's healthcare sector suggests that the company is looking to adapt to changes and challenges in the industry.
• The transition is significant for SBP Group, as it represents a departure from its traditional generics-focused model and a move towards more innovative and potentially lucrative drug development opportunities.
• The announcement was made in the context of China's evolving healthcare landscape, where there is a growing emphasis on innovation and development of new treatments.